ISR Articles
-
Reasons CDMOs Lose Bioprocessing Bids
9/15/2020
In Q2 2020, ISR asked 100 respondents who outsource bioprocessing what is the main reason a CDMO may lose the bid for an outsourced bioprocessing project. Regulatory violations / FDA form 483 warnings topped the list, capturing 32% of respondents’ votes.
-
Biologic Drug Product Outsourcing
5/12/2020
In Q4 2019, ISR asked 163 outsourcers of biologic drug product about the proportion of manufacturing allocated across three different approaches to outsourcing: tactical outsourcing, preferred providers, and strategic partnerships. The data show that the largest proportion of work is allocated to preferred providers (37%), followed by strategic partnerships (33%).
-
ISR's Contract Manufacturing Databook
4/1/2020
It can be difficult to find industry specific, easy to interpret, trustworthy market data. Read the available eBook to discover free drug development and manufacturing facts, figures, and expert perspectives.
-
Changes In Manufacturing Pipeline Focus
3/13/2020
This infographic reveals how many buyers of outsourced manufacturing services will increase their focus on biomanufacturing (including biosimilars), combined therapies, and focused therapies like ADCs.
-
3 Year Rolling Average – Biologic API Customer Loyalty
1/14/2020
ISR asked sponsors who outsource biologic API for insight into their customer loyalties. Here's how those outsourcers ranked. (From ISR's Biologic API Contract Manufacturer Quality Benchmarking, 4th Edition)
-
Top Five Oral Dosage Forms By Portfolio Composition
9/12/2019
The top five oral dosage forms account for more than half of products in oral dose portfolios and are: tablets, capsules, controlled release tablets, controlled release capsules, and immediate release tablets.
-
How Experience, Capacity Shape Sterile Injectables Outsourcing
7/16/2019
ISR asked 43 outsourcers of sterile injectable drug products why manufacturing might be split between in-house and external resources. More than half said their companies lack capacity.
-
How Do Experience And Capacity Impact Small Molecule API Outsourcing?
7/16/2019
ISR asked 60 outsourcers of small molecule drug substance manufacturing to select from four different reasons that manufacturing may be split between in-house and external resources.
-
Top Five Satisfaction Drivers For Outsourced Oral Dose Manufacturing
6/14/2019
In Q1, 2019, ISR surveyed 102 sponsors who outsource oral dosage form manufacturing to improve our understanding of what influences customers satisfaction.
-
Top Five Satisfaction Drivers For Outsourced Bioprocessing
6/14/2019
ISR surveyed 100 sponsors who outsource bioprocessing to learn what drives CMO satisfaction. Learn why Quality compliance and Technical capabilities and technical service lead satisfaction drivers.